Sarcomas represent a diverse range of soft tissue tumors, presenting significant diagnostic challenges for clinicians and oncology researchers.

 Our range of products and services dedicated to sarcoma diagnostics offers innovative solutions for accurate identification and in-depth characterization of these complex conditions.

Thanks to advanced techniques such as next-generation sequencing (NGS) and fusion transcript detection, we offer tools for precise characterization of sarcomatous subtypes, paving the way for targeted, individualized treatments.

Fusion transcripts are present in around a third of soft tissue tumors and are often associated with specific histological subtypes, dictating targeted therapies. Detection of the fusions detected is now automated, and quantitative information is combined to improve treatment prospects for patients affected by these oncological conditions. Our diagnostic tools enhance treatment decision-making and improve outcomes for patients affected by sarcomas. As we continually strive to advance sarcoma diagnostics, we also provide comprehensive reports that integrate molecular and clinical data, as well as expert consultation and guidance from our team of sarcoma specialists. Our goal is to support the best possible care for sarcoma patients, by delivering reliable, timely, and personalized diagnostic information.